Embecta said its patch pump was designed with feedback from people with Type 2 diabetes. The company presented data in June finding that 200-unit reservoirs have enough capacity for only 38% of adults ...
9d
New Zealand Society for the Study of Diabetes (NZSSD) welcomes Pharmac’s decision to fund continuous glucose monitors and insulin pumps, which allow automated insulin delivery, for people with type 1 ...
Brown Capital Management, an investment management company, released its “The Brown Capital Management Mid Company Fund” ...
Modular Medical shares rose after hours as the company received Food and Drug Administration clearance for its MODD1 insulin pump. The stock was up 27%, to $2.49, surpassing the prior 52-week high ...
"For too long, the benefits of superior glycemic control achieved by insulin pumps have, due to cost and complexity, been restricted to only the most sophisticated, motivated and well-insured users.
Embecta has secured an FDA clearance for its first wearable insulin delivery system, with a patch pump designed for people with either Type 1 or Type 2 diabetes. The fully disposable device ...
300-unit insulin reservoir is more suitable for people with T2D who are interested in moving from multiple daily injections (MDI) to pump therapy, based on an average daily dose of 95.9 units of ...
Indicated for adults who require insulin to manage diabetes, including both type 1 (T1D) and type 2 (T2D), the system includes a tubeless patch pump design with a 300-unit insulin reservoir that ...
SATURDAY, Aug. 31, 2024 (HealthDay News) -- Insulin can be a critical part of managing diabetes, but patients may not know all of the ins and outs of using the medication effectively. Luckily, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback